Table 1.
Clinical and pathological characteristics of the study cohort
| Patients, n = 33 | Value |
|---|---|
| Age (years) | |
| Median | 70 |
| Range | 53-82 |
| ECOG performance status, n (%) | |
| 0 | 23 (69.6) |
| 1 | 5 (15.2) |
| 2 | 5 (15.2) |
| Gleason score at diagnosis, n (%) | |
| Unknown | 3 (9.1) |
| ≤ 7 | 11 (33.3) |
| ≥ 8 | 19 (57.6) |
| Primary therapy, n (%) | |
| RP | 9 (27.3) |
| EBRT | 4 (12.1) |
| Palliative | 20 (60.6) |
| Metastatic sites, n (%) | |
| Soft tissue | 3 (9.0) |
| Bone + LN | 15 (45.5) |
| Bone + Visceral ± LN | 15 (45.5) |
| Biochemical markersa | |
| PSA [ng/dl] | 140 |
| 0.1-3378 | |
| Lactate dehydrogenase [U/l] | 320 |
| 218-1900 | |
| Alkaline phosphatase [U/l] | 164 |
| 50-1466 | |
| Hemoglobin [g/dl] | 11.6 |
| 8.5-16.1 |
ECOG, eastern cooperative oncology group; EBRT, external beam radiotherapy; LN, lymph node metastases; PSA, prostate-specific antigen; RP, radical prostatectomy; n, number
avalues given as median and range